Related Experiment Video
Updated: Jun 18, 2026
05:53
Use of In vivo Imaging to Monitor the Progression of Experimental Mouse Cytomegalovirus Infection in Neonates
Published on: July 6, 2013
CML in pregnancy and childhood
1Department of Haematology, Imperial College, Hammersmith Hospital, Ducane Road, London W120NN, UK. j.apperley@imperial.ac.uk
Best Practice & Research. Clinical Haematology
|December 5, 2009
Summary
Imatinib is generally safe for male fertility and parenting, but poses risks to developing fetuses during pregnancy. For children with chronic myeloid leukemia (CML), imatinib is a viable treatment option before considering transplant.
Area of Science:
- Oncology
- Hematology
- Reproductive Health
Background:
- Tyrosine kinase inhibitors (TKIs), such as imatinib, have improved survival rates for cancer patients.
- Increased survival necessitates addressing quality of life issues, including fertility and parenting.
- Limited human data exist on imatinib's effects on fertility and pregnancy outcomes.
Purpose of the Study:
- To review the available data on imatinib's impact on fertility and pregnancy in cancer patients.
- To discuss the implications of imatinib use for parenting and the management of pediatric chronic myeloid leukemia (CML).
Main Methods:
- Review of existing animal and human data regarding imatinib's effects on male and female fertility.
- Analysis of reported outcomes for children conceived by parents using imatinib.
- Evaluation of imatinib's efficacy and safety in pediatric CML management.
Main Results:
- Animal studies suggest imatinib does not impair fertility at standard doses.
- Children born to fathers taking imatinib appear healthy; discontinuation is not advised.
- Pregnancy exposure to imatinib in women is linked to a concerning cluster of rare congenital malformations, precluding its recommendation during organogenesis.
Conclusions:
- Imatinib is generally considered safe for male fertility and parenting.
- Imatinib is not recommended during pregnancy due to potential teratogenic effects.
- Imatinib is an effective treatment for pediatric CML, often preferred over transplant for initial therapy.
Related Concept Videos
01:27Cytomegalovirus Disease
Cytomegalovirus (CMV) disease is caused by human cytomegalovirus, a double-stranded DNA virus of the Herpesviridae family. While primary CMV infection is often asymptomatic in immunocompetent individuals, the virus can cause severe disease in neonates and immunocompromised patients. CMV is the most common cause of congenital viral infection in the United States, and a major pathogen in solid organ and hematopoietic stem cell transplant recipients.CMV is transmitted via bodily fluids, sexual...
01:22Development of Immunocompetence
The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
01:15Differentiation of Common Myeloid Progenitor Cells
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
01:19Mitral Valve Prolapse III: Nursing Management
The nursing management of Mitral Valve Prolapse, or MVP, centers around patient education, symptom monitoring, and lifestyle modifications.Patient Education on MVP Diagnosis and Heredity: Nurses should provide comprehensive education about MVP, a condition where the mitral valve does not close appropriately during heartbeats. This education often includes the condition's pathophysiology, symptoms, and potential complications, like arrhythmias or mitral regurgitation. Though not fully...
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...